They may make TOTAL sense as it relates to IPCI's actual reported revenues...but they also simultaneously prove that the reported Bloomberg numbers are totally and completely erroneous...because just strictly based on the reported Bloomberg PAR/FocalinXR sales for IPCI's fiscal Q3...the revs from the PAR/FocalinXR deal should've come in around $1.7M alone without even factoring in Mallinkrodt's slow rollout of SeroquelXR in the quarter.
Market Data 
Markets 
AI
